Automate Your Wheel Strategy on RXST
With Tiblio's Option Bot, you can configure your own wheel strategy including RXST - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RXST
- Rev/Share 3.9103
- Book/Share 6.895
- PB 1.8927
- Debt/Equity 0.0431
- CurrentRatio 12.6826
- ROIC -0.1268
- MktCap 530312850.0
- FreeCF/Share -0.5084
- PFCF -25.7471
- PE -19.9153
- Debt/Assets 0.0385
- DivYield 0
- ROE -0.0954
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | RXST | Wells Fargo | Equal Weight | Overweight | -- | $25 | May 19, 2025 |
| Initiation | RXST | Piper Sandler | -- | Neutral | -- | $18 | April 15, 2025 |
| Downgrade | RXST | UBS | Buy | Neutral | -- | $16 | April 9, 2025 |
| Downgrade | RXST | JP Morgan | Overweight | Underweight | $40 | $17 | April 4, 2025 |
| Downgrade | RXST | BofA Securities | Buy | Underperform | $36 | $22 | April 3, 2025 |
| Downgrade | RXST | Stifel | Buy | Hold | $65 | $40 | Dec. 20, 2024 |
| Downgrade | RXST | Wells Fargo | Overweight | Equal Weight | $56 | $42 | Dec. 11, 2024 |
| Initiation | RXST | UBS | -- | Buy | -- | $52 | Dec. 6, 2024 |
| Reiterated | RXST | Needham | -- | Buy | $54 | $66 | Aug. 20, 2024 |
News
FMS vs. RXST: Which Stock Is the Better Value Option?
Published: July 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for stocks in the Medical - Instruments sector might want to consider either Fresenius (FMS) or RxSight, Inc. (RXST). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
FMS or RXST: Which Is the Better Value Stock Right Now?
Published: June 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for stocks in the Medical - Instruments sector might want to consider either Fresenius (FMS) or RxSight, Inc. (RXST). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
RxSight, Inc. (RXST) Q1 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
RxSight, Inc. (NASDAQ:RXST ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Oliver Moravcevic - Vice President, Investor Relations Ron Kurtz - President & Chief Executive Officer Shelley Thunen - Chief Financial Officer Conference Call Participants Xuyang Li - Jefferies Patrick Wood - Morgan Stanley Steve Lichtman - Oppenheimer David Saxon - Needham & Company Adam Maeder - Piper Sandler Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Craig Bijou - Bank of America Tom Stephan - Stifel Operator Thank you for standing by. At this time, I would like to welcome everyone to …
Read More
RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
RxSight, Inc. (RXST) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.12 per share a year ago.
Read More
RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance
Published: April 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
ALISO VIEJO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary revenue results for the first quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Thursday, April 3, 2025, at 8:00 a.m. Eastern Time.
Read More
RxSight, Inc. (RXST) Misses Q4 Earnings Estimates
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Negative
RxSight, Inc. (RXST) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to loss of $0.26 per share a year ago.
Read More
About RxSight, Inc. (RXST)
- IPO Date 2021-07-30
- Website https://www.rxsight.com
- Industry Medical - Devices
- CEO Ronald M. Kurtz
- Employees 498